Table of Contents
- 1. Cytarabine (CAS 147-94-4): Product Overview & Specifications
- 2. Key Therapeutic Applications & Clinical Use Cases
- 3. Pharmacological Mechanism & Biochemical Properties
- 4. Clinical Case Studies & Patient Outcomes
- 5. Administration Protocols & Safety Guidelines
- 6. Supplier Comparison & Procurement Guidance
- 7. Contact for Technical Support & Bulk Orders
1. Cytarabine (CAS 147-94-4): Product Overview & Specifications
Chemical Specifications
| Parameter | Details |
|---|---|
| CAS Number | 147-94-4 |
| Molecular Formula | C9H13N3O5 |
| Purity Grade | ≥98% (HPLC), Pharmaceutical Grade |
| Appearance | White to off-white crystalline powder |
| Solubility | 50 mg/mL in water (clear, colorless solution) |
Comparative Analysis of Commercial Grades
| Supplier | Purity | Packaging | Price Range |
|---|---|---|---|
| PharmaCo A | 98.5% | 1kg/vial | $850-$1,200/kg |
| BioChem Ltd | 99.2% | 500g/jar | $1,100-$1,500/kg |
| OncoSolutions | 99.9% | 100mg/ampule | $2.50/mg |
2. Key Therapeutic Applications & Clinical Use Cases
Primary Medical Indications
- First-line treatment for acute myeloid leukemia (AML)
- Component in ALL (Acute Lymphocytic Leukemia) protocols
- Lymphoma combination therapies
Research Applications
- DNA synthesis inhibition studies
- Chemotherapy resistance mechanisms research
- Combination therapy efficacy trials
3. Pharmacological Mechanism & Biochemical Properties
Mode of Action
- Competitive inhibition of DNA polymerase
- Incorporation into DNA strands causing chain termination
- S-phase specific cytotoxicity
Pharmacokinetic Profile
| Parameter | Value |
|---|---|
| Half-life | 1-3 hours (IV administration) |
| Protein Binding | 13% |
| Metabolism | Hepatic deamination |
4. Clinical Case Studies & Patient Outcomes
Case Study 1: AML Remission Induction
- Patient: 58yo male with newly diagnosed AML
- Protocol: 7+3 regimen (100mg/m² continuous infusion)
- Outcome: Complete remission achieved in 28 days
Case Study 2: Refractory ALL Treatment
- Patient: 12yo female with relapsed B-cell ALL
- Protocol: High-dose cytarabine (3g/m² every 12h)
- Outcome: 90% blast reduction post-cycle 2
5. Administration Protocols & Safety Guidelines
Dosing Recommendations
| Regimen | Dosage | Frequency |
|---|---|---|
| Standard AML | 100mg/m² | Continuous IV (days 1-7) |
| High-dose | 3g/m² | 2hr infusion q12h (days 1,3,5) |
Adverse Effect Management
- Myelosuppression monitoring protocol
- Cerebellar toxicity screening procedures
- Conjunctivitis prevention strategies
6. Supplier Comparison & Procurement Guidance
Global Supplier Analysis
| Vendor | Certifications | Lead Time | MOQ |
|---|---|---|---|
| OncoPharm | FDA, EMA, PMDA | 4-6 weeks | 100g |
| BioThera | WHO-GMP | 2-3 weeks | 500g |
7. Contact for Technical Support & Bulk Orders
For formulation assistance or commercial inquiries:
Email: info@vivalr.com
Tel: (86) 15866781826
Request current COA documentation and stability data sheets.



评论
目前还没有评论。